AnkurRasikParikhDO

Oncology • Willow Grove, PA

Gastrointestinal Cancer

Associate Medical Director, Precision Medicine

Join to view full profile

Dr. Parikh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Parikh's full profile

Already have an account?

Office
Asplundh Cancer Pavilion
3941 Commerce Ave
Willow Grove, PA 19090
Is this information wrong?

Summary

I am a medical oncologist and associate medical director of precision medicine. I believe that genomic based therapy and immuno-oncology are rapidly changing the landscape of cancer treatment. I am involved with clinical research and enjoy speaking at national conferences and seminars on the topics of precision medicine and oncology.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
OhioHealth/Riverside Methodist HospitalResidency, Internal Medicine, 2006 - 2009
A. T. Still University Kirksville College of Osteopathic MedicineClass of 2006

Certifications & Licensure

PA State License 2012 - 2024
MD State License 2009 - 2013
OH State License 2006 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome Start of enrollment: 2005 Jul 21
Completed
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Start of enrollment: 2016 Mar 14
Recruiting
Phase 2
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2017 Mar 01
Completed
Phase 3

Publications & Presentations

PubMed

5 citations
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
K Murugesan, A Necchi, T C Burn, O Gjoerup, R Greenstein, M Krook, J A López, M Montesion, H Nimeiri, A R Parikh, S Roychowdhury, S Schwemmers, I M Silverman, A Vogel> ;ESMO Open. 2022 Dec 1
1 citations
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.
Alana Vicente, Bhavisha A Patel, Fernanda Gutierrez-Rodrigues, Emma Groarke, Valentina Giudice, Jennifer Lotter, Xingmin Feng, Sachiko Kajigaya, Barbara Weinstein, Eve...> ;Haematologica. 2020 Dec 1
15 citations
Lung Cancer Genomics.
Ankur R. Parikh> ;Acta Medica Academica. 2019 Jun 26
5 citations
Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab
Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R. Parikh, Aarthi Shenoy, Julie Thompson, Barbara Weinstein, Phillip Scheinberg, A. John Barrett, Rona...> ;Blood Advances. 2019 Apr 9
9 citations
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden.
Ankur R. Parikh, Siraj M. Ali, Alexa B. Schrock, Lee A. Albacker, Vincent A. Miller, Phil Stephens, Pamela A. Crilley, Maurie Markman> ;Lung Cancer. 2018 May 18
38 citations
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
Jiaxin Niu, Grant Andres, Kim Kramer, Madappa N. Kundranda, Ricardo H. Alvarez, Eiko Klimant, Ankur R. Parikh, Bradford A. Tan, Edgar D. Staren, Maurie Markman> ;Oncotargets and Therapy. 2015 Nov 11
272 citations
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
Ronan Desmond, Danielle M. Townsley, Bogdan Dumitriu, Matthew J. Olnes, Phillip Scheinberg, Margaret Bevans, Ankur R. Parikh, Kinneret Broder, Katherine R. Calvo, Coli...> ;Blood. 2014 Mar 20
35 citations
Immunomodulatory Treatment of Myelodysplastic Syndromes: Antithymocyte Globulin, Cyclosporine, and Alemtuzumab
Ankur R. Parikh, Matthew J. Olnes, A. John Barrett> ;Seminars in Hematology. 2012 Oct 1
306 citations
Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
Matthew J. Olnes, Phillip Scheinberg, Katherine R. Calvo, Ronan Desmond, Yong Tang, Bogdan Dumitriu, Ankur R. Parikh, Susan Soto, Angelique Biancotto, Xingmin Feng, Ja...> ;The New England Journal of Medicine. 2012 Jul 4
1 citations
A suspicion of chikungunya leading to a diagnosis of angioimmunoblastic T-cell lymphoma.
Fadi Braiteh, Ankur R. Parikh, Peter McLaughlin> ;Acta Oncologica. 2009 Jul 8
Join now to see all

Journal Articles

Applying Genomics to Leukemias & Lymphomas
Parikh AR, Oncology Times, 9/5/2018
Under representation of Elderly Population in Clinical Trials
Parikh AR, Oncology Times, 7/5/2018
A Look at Cancer Immunotherapy in Elderly Patients
Parikh AR, Oncology Times, 4/20/2018

Abstracts/Posters

Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System
Parikh AR, et al., European Society for Medical Oncology 2018 Congress, Munich, Germany, 10/20/2018

Authored Content

We need more answers about immunotherapy for elderly6/22/2018

Press Mentions

How to Access Cutting-Edge Cancer Treatments and Clinical Trials in PhillyOctober 31st, 2020
FDA Approves Foundation Medicine’s Genetic Diagnostic Test as CMS Paves the Way for CoverageDecember 1st, 2017